Thomas E Witzig Selected Research

Thrombocytopenia (Thrombopenia)

8/2017	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
4/2011	Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.
8/2008	Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
1/2007	The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
4/2006	Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
8/2005	Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
12/2003	Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
4/2003	Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
9/2002	Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
6/2002	Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas E Witzig Research Topics

Disease

84	Neoplasms (Cancer) 05/2024 - 02/2002
65	Lymphoma (Lymphomas) 05/2024 - 01/2002
63	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023 - 01/2002
38	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 05/2022 - 07/2007
35	Multiple Myeloma 01/2021 - 11/2002
26	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2024 - 06/2002
19	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 11/2023 - 05/2005
19	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2022 - 01/2002
18	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 04/2024 - 11/2002
13	Disease Progression 01/2020 - 09/2002
12	Infections 05/2024 - 06/2002
12	Hodgkin Disease (Hodgkin's Disease) 01/2024 - 10/2005
12	Immunoglobulin Light-chain Amyloidosis 06/2014 - 02/2003
11	B-Cell Lymphoma (Lymphoma, B Cell) 04/2024 - 01/2002
10	Thrombocytopenia (Thrombopenia) 08/2017 - 06/2002
7	Neutropenia 05/2022 - 01/2007
5	Fatigue 05/2022 - 04/2005
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 04/2003
5	Colonic Neoplasms (Colon Cancer) 03/2007 - 09/2003
4	Acute Kidney Injury (Acute Renal Failure) 02/2024 - 09/2021
4	Febrile Neutropenia 05/2022 - 07/2005
4	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 07/2006
4	Immunoglobulin G4-Related Disease 12/2018 - 06/2015
4	Anemia 08/2017 - 01/2003
4	Necrosis 01/2017 - 10/2003
4	Smoldering Multiple Myeloma 01/2016 - 08/2004
4	Paraproteinemias (Monoclonal Gammopathy) 12/2012 - 01/2002
4	Autoimmune Diseases (Autoimmune Disease) 01/2011 - 09/2003
4	Carcinoma (Carcinomatosis) 03/2007 - 05/2002
3	Sepsis (Septicemia) 04/2021 - 06/2002
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 09/2007
3	T-Cell Lymphoma (Lymphoma, T Cell) 07/2015 - 10/2009
3	Genetic Translocation (Chromosomal Translocation) 01/2015 - 09/2013
3	POEMS Syndrome (Syndrome, POEMS) 07/2013 - 04/2003
3	Chromosome Aberrations (Chromosome Abnormalities) 02/2011 - 05/2003
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 04/2008 - 06/2004
2	COVID-19 04/2024 - 06/2023
2	Diarrhea 05/2022 - 03/2013

Drug/Important Bio-Agent (IBA)

53	Rituximab (Mabthera)FDA Link 01/2024 - 01/2002
24	Lenalidomide (CC 5013)FDA Link 01/2022 - 01/2007
23	Proteins (Proteins, Gene)FDA Link 04/2024 - 04/2003
21	ibritumomab tiuxetan (Zevalin)FDA Link 01/2023 - 02/2002
16	Dexamethasone (Maxidex)FDA LinkGeneric 11/2018 - 11/2002
13	CytokinesIBA 04/2024 - 08/2004
11	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 08/2011
11	TOR Serine-Threonine KinasesIBA 01/2019 - 08/2005
11	Everolimus FDA Link 10/2018 - 07/2006
10	Immunoglobulin M (IgM)IBA 01/2020 - 01/2002
10	Monoclonal AntibodiesIBA 10/2008 - 08/2003
9	Biomarkers (Surrogate Marker)IBA 07/2022 - 12/2006
8	Methotrexate (Mexate)FDA LinkGeneric 02/2024 - 06/2004
8	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 12/2005
8	Immunoglobulins (Immunoglobulin)IBA 11/2018 - 04/2006
8	Thalidomide (Thalomid)FDA Link 10/2010 - 11/2002
7	Yttrium-90IBA 01/2023 - 08/2002
7	Prednisone (Sone)FDA LinkGeneric 01/2021 - 10/2011
7	YttriumIBA 07/2013 - 02/2002
6	ibrutinibIBA 10/2021 - 01/2017
6	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 12/2005
6	Cyclin D1IBA 10/2020 - 08/2005
6	Bortezomib (Velcade)FDA Link 01/2020 - 07/2005
6	Mechanistic Target of Rapamycin Complex 1IBA 10/2018 - 10/2009
6	temsirolimus FDA Link 04/2011 - 08/2005
5	AnthracyclinesIBA 04/2024 - 08/2014
5	B-Cell Activating FactorIBA 05/2009 - 02/2006
4	Anti-Bacterial Agents (Antibiotics)IBA 05/2024 - 06/2002
4	Immune Checkpoint InhibitorsIBA 01/2024 - 03/2016
4	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 09/2006
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2019 - 07/2006
4	LigandsIBA 01/2017 - 02/2008
4	Sirolimus (Rapamycin)FDA Link 03/2012 - 07/2006
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2012 - 08/2004
4	MTOR InhibitorsIBA 04/2011 - 10/2009
4	CD20 AntigensIBA 03/2008 - 01/2006
3	Messenger RNA (mRNA)IBA 01/2023 - 08/2005
3	Bendamustine Hydrochloride FDA Link 01/2022 - 08/2018
3	InterferonsIBA 01/2022 - 09/2012
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 04/2021 - 03/2007
3	TroponinIBA 01/2019 - 09/2004
3	SteroidsIBA 12/2018 - 03/2008
3	Immunoglobulin G (IgG)IBA 04/2016 - 03/2008
3	Alemtuzumab (Campath)FDA Link 01/2015 - 08/2003
3	Complement System Proteins (Complement)IBA 09/2012 - 10/2008
3	Vitamin D FDA LinkGeneric 07/2012 - 09/2010
3	Interleukin-12 (IL 12)IBA 04/2012 - 01/2002
3	Interleukin-10 (Interleukin 10)IBA 03/2012 - 10/2009
3	Interleukin-6 (Interleukin 6)IBA 11/2011 - 10/2003
3	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2010 - 05/2003
3	Phosphotransferases (Kinase)IBA 08/2008 - 05/2003
2	Biological FactorsIBA 01/2024 - 09/2012
2	Radioisotopes (Radionuclides)IBA 08/2023 - 07/2011
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2022 - 11/2012

Therapy/Procedure

89	Therapeutics 05/2024 - 01/2002
27	Radioimmunotherapy 01/2024 - 02/2002
23	Drug Therapy (Chemotherapy) 01/2022 - 06/2002
11	Stem Cell Transplantation 01/2022 - 12/2002
8	Radiotherapy 05/2024 - 12/2003
7	Aftercare (After-Treatment) 02/2024 - 04/2003
6	Immunotherapy 01/2024 - 05/2002
3	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 04/2006 - 05/2004